|
|
|
|
Cell therapy delays more often stem from manufacturing readiness, regulatory demands, and supply chain complexity than from clinical results. Learn five common missteps and how early decisions shape late-stage outcomes.
|
|
|
|
|
Major pharma deals have spotlighted in vivo CAR-T, but the technical winners remain undecided. See how delivery, CMC execution, and regulatory readiness now drive differentiation.
|
|
|
|
|
Many 2D, serum-based MSC and EV processes resist GMP-compliant transfer to 3D. Discover whether a xeno-free, automated approach can maintain cell and vesicle quality through bioreactor scale-up.
|
|
|
|
|
|
|
What makes a lentiviral vector fit for in vivo use? Using client case studies, Lonza’s Bingnan Gu shows how feasibility-first development and enhanced downstream processing can help bridge concept and clinic.
|
|
|
|
|
A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.
|
|
|
|
|
|
|
Transient transfection brings GMP plasmid dependency, variability, and high costs at scale. See how a chemically induced stable producer cell line scales across bioreactors and stays clonally stable for 30+ passages.
|
|
|
